908 related articles for article (PubMed ID: 22367731)
1. The 2012 hormone therapy position statement of: The North American Menopause Society.
North American Menopause Society
Menopause; 2012 Mar; 19(3):257-71. PubMed ID: 22367731
[TBL] [Abstract][Full Text] [Related]
2. The 2017 hormone therapy position statement of The North American Menopause Society.
Menopause; 2018 Nov; 25(11):1362-1387. PubMed ID: 30358733
[TBL] [Abstract][Full Text] [Related]
3. The 2017 hormone therapy position statement of The North American Menopause Society.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel
Menopause; 2017 Jul; 24(7):728-753. PubMed ID: 28650869
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2010 Mar; 17(2):242-55. PubMed ID: 20154637
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.
Utian WH; Archer DF; Bachmann GA; Gallagher C; Grodstein Fn; Heiman JR; Henderson VW; Hodis HN; Karas RH; Lobo RA; Manson JE; Reid RL; Schmidt PJ; Stuenkel CA;
Menopause; 2008; 15(4 Pt 1):584-602. PubMed ID: 18580541
[TBL] [Abstract][Full Text] [Related]
6. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(2):168-82. PubMed ID: 17259911
[TBL] [Abstract][Full Text] [Related]
7. The 2022 hormone therapy position statement of The North American Menopause Society.
“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel
Menopause; 2022 Jul; 29(7):767-794. PubMed ID: 35797481
[TBL] [Abstract][Full Text] [Related]
8. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
[TBL] [Abstract][Full Text] [Related]
9. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society.
Menopause; 2021 Sep; 28(9):973-997. PubMed ID: 34448749
[TBL] [Abstract][Full Text] [Related]
10. Role of progestogen in hormone therapy for postmenopausal women: position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2003; 10(2):113-32. PubMed ID: 12627037
[TBL] [Abstract][Full Text] [Related]
11. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2006; 13(3):340-67; quiz 368-9. PubMed ID: 16735931
[TBL] [Abstract][Full Text] [Related]
12. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
13. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
14. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
The NAMS 2020 GSM Position Statement Editorial Panel
Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
[TBL] [Abstract][Full Text] [Related]
15. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Barry MJ; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Krist AH; Kurth AE; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW
JAMA; 2017 Dec; 318(22):2224-2233. PubMed ID: 29234814
[TBL] [Abstract][Full Text] [Related]
16. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
[TBL] [Abstract][Full Text] [Related]
17. The role of calcium in peri- and postmenopausal women: 2006 position statement of the North American Menopause Society.
North American Menopause Society
Menopause; 2006; 13(6):862-77; quiz 878-80. PubMed ID: 17106282
[TBL] [Abstract][Full Text] [Related]
18. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
Gambrell RD
Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
[TBL] [Abstract][Full Text] [Related]
19. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
[TBL] [Abstract][Full Text] [Related]
20. NAMS 3rd Utian Translational Science Symposium, October 2016, Orlando, Florida A conversation about hormone therapy: is there an appropriate dose, route, and duration of use?
The North American Menopause Society (NAMS)
Menopause; 2017 Nov; 24(11):1221-1235. PubMed ID: 28968302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
